Mammography remains the gold standard for breast cancer screening — including for patients with breast implants. Standard mammographic technique modifies for implants using implant displacement views (Eklund views) that move the implant out of the imaging field. Implants reduce visualization of approximately 25-30% of breast tissue compared to non-augmented breasts. This guide details what augmented patients need to know about mammography: scheduling, technique, what radiologists see, and when supplementary imaging makes sense.
Breast augmentation does not increase breast cancer risk — but it doesn't reduce risk either. Standard population breast cancer screening recommendations apply.
Cancer risk after augmentation. Multiple large studies show no increased breast cancer risk in augmented patients vs general population. Some studies suggest slightly reduced incidence, possibly due to selection bias (augmented patients tend toward better baseline health). Regardless, baseline cancer risk persists — augmentation doesn't protect.
Screening guidelines. Standard screening guidelines apply: USPSTF recommends mammography from age 40-50 (varies by guideline) with biennial frequency. UK NHS: from age 50 every 3 years. EU programs: from 50, every 2-3 years. Augmentation doesn't change guideline-based screening initiation or frequency.
What changes with implants. Imaging technique modified (Eklund views), interpretation slightly more challenging, supplementary imaging sometimes warranted. Cancer detection capability somewhat reduced but still excellent.
What doesn't change. Cancer screening still essential. Regular mammography still recommended. Self-examination still useful (with augmentation-specific awareness). Clinical breast examination still beneficial.
Implant rupture surveillance is separate. Mammographic screening detects breast cancer; doesn't reliably detect silent implant rupture. Specific implant surveillance (MRI or ultrasound at 5-6 year intervals) is separate from cancer screening. Both protocols can run in parallel.
The technical adaptation for mammography in augmented patients.
Standard mammography views. Craniocaudal (CC) — top-to-bottom view. Mediolateral oblique (MLO) — angled side view. These are the two standard views per breast in routine screening, four total images.
Eklund (implant displacement) views. Additional views with implant pushed back against chest wall, breast tissue pulled forward into compression plates. Allows imaging of breast tissue without implant interference. Two additional views per breast (CC and MLO Eklund) — eight total images for augmented patients.
Why both standard and Eklund views are needed. Standard views show entire breast including implant — useful for assessing implant integrity, detecting tissue around implant, evaluating tissue immediately adjacent to implant. Eklund views maximize visualization of breast tissue itself by displacing implant. Combined views provide comprehensive evaluation.
Technical performance. Eklund technique requires trained mammography technologist. Compression different from standard — less compression on breast tissue (avoiding implant pressure). Patient experience similar to standard mammography. Some patients describe Eklund views as slightly less uncomfortable than standard compression.
Specific limitations. Submuscular implants harder to displace fully than subglandular — slightly less effective Eklund views. Capsular contracture limits implant displacement — significantly contracted implants can't be moved out of view. Very large implants relative to breast tissue: limited tissue available for imaging.
Specific information about mammographic visualization with implants.
What's clearly visible. Implant outline and shape (assess for rupture indicators). Breast tissue immediately surrounding implant. Breast tissue in displaced views (most of remaining breast). Calcifications (early cancer indicators) if not obscured by implant. Skin and skin-level findings.
What's harder to see. Breast tissue immediately behind implant (chest wall side). Some posterior breast tissue. Calcifications immediately adjacent to or behind implant. Capsule features (often thin and not visible on mammography).
Visualization rate. Augmented patients: approximately 70-75% of breast tissue visualized vs 95%+ in non-augmented patients. The 25-30% gap is primarily posterior tissue immediately behind implant.
Cancer detection sensitivity. Slightly reduced compared to non-augmented breasts but still high (approximately 85-90% of cancers detectable vs 95%+ in non-augmented breasts). Most missed cancers are in tissue immediately behind implant.
What this means practically. Most cancers still detectable through standard mammography. Specific scenarios warrant supplementary imaging (high-risk patients, suspicious findings, very dense tissue). Self-examination remains useful for detecting cancers in posterior tissue not well-imaged.
Specific findings to report. Patients should inform mammography facility about: implant brand and type if known, year of placement, any previous abnormal mammograms, family cancer history. Helps radiologist interpretation.
When mammography alone may not be sufficient.
Breast MRI. Highly sensitive for cancer detection. Not affected by implants for tissue visualization. Used for: high-risk patients (BRCA mutation, strong family history), evaluation of suspicious mammographic findings, dense breast tissue with reduced mammographic sensitivity. Cost: $400-$1,500 depending on country.
Breast ultrasound. Useful supplement to mammography. Better at detecting cancers in dense tissue or near implants where mammography is limited. Used routinely as supplement in many countries (Germany, France, Eastern Europe). Cost: $150-$400.
Tomosynthesis (3D mammography). Modern mammography technology that produces 3D images from multiple angles. Improved cancer detection in dense tissue and around implants. Not specifically for implant patients but somewhat better than 2D mammography for them. Increasingly available; sometimes covered by insurance.
Contrast-enhanced mammography. Specialized technique using IV contrast to highlight tumors. Used in specific scenarios: equivocal findings, dense tissue limitations, avoidance of MRI when contraindicated. Specialized centers only.
Routine vs targeted use. Most augmented patients have standard mammography only. Specific situations warrant supplementary imaging: high-risk patients (annual MRI usually added), suspicious mammographic findings (targeted ultrasound), specific tissue characteristics (dense tissue may add ultrasound).
Cost considerations. NHS (UK) doesn't routinely add supplementary imaging — only with specific indications. EU public systems variable. USA insurance typically covers based on medical necessity. Self-pay supplementary imaging available in most countries.
Specific guidance for different patient scenarios.
First mammogram after augmentation. Wait minimum 6 months after surgery for first post-augmentation mammogram. Earlier imaging may show post-operative changes that mimic abnormalities. After 6 months, baseline mammogram appropriate.
Discussing implants with mammography facility. Inform facility when scheduling. Provide implant brand and type if known. Schedule with technologists experienced in Eklund views. Some facilities specialize in augmented patients; others have less experience.
Frequency of mammography. Same guideline-based frequency as non-augmented women. UK NHS: every 3 years from 50. USA: variable by guideline. Don't reduce frequency because of augmentation. Don't increase frequency unless specific indication.
Self-examination considerations. Augmented breasts feel different from natural breasts — implant edge palpable, areas of natural tissue between implant and skin. Establish baseline self-examination 3-6 months post-op when settling complete. Look for changes from baseline rather than interpreting current state in isolation.
What changes warrant immediate evaluation. New palpable lump distinct from implant edge. Skin changes (dimpling, redness, inflammation). Persistent pain in specific area. Asymmetric changes between breasts. Nipple discharge. Same warning signs as non-augmented breasts.
For revision augmentation patients. Continue same screening schedule. Each implant change is opportunity to update mammographic baseline. Scarring from multiple surgeries doesn't typically interfere with cancer detection significantly.
Send a WhatsApp message to Dr. Erdal personally — every patient enquiry is reviewed and answered by Dr. Erdal directly, within 24 hours.